Safinamide

Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 μM) over MAO-A (IC50=580 μM) [1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 μM) than at resting (IC50=262 μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

Product Specifications

CAS Number

[133865-89-1]

Product Name Alternative

FCE 26743; EMD 1195686

UNSPSC

12352005

Hazard Statement

H302, H319

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Safinamide.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C([C@@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C)N

Molecular Formula

C17H19FN2O2

Molecular Weight

302.34

Precautions

H302, H319

References & Citations

[1]Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50 (20), 4909-4916.|[2]C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67 (7 Suppl 2) :S18-23.|[3]Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364 (2) :198-206.